
The Amrita Institute of Medical Sciences (AIMS) has carried out a rare treatment
procedure to save a 19-year-old girl suffering from acute blood cancer or acute
myeloid leukaemia.
The treatment protocol,
'Microtransplant', involves normal chemotherapy followed by infusion of
intentionally mismatched cells.
Advertisement
The unique procedure is based on immunological killing of leukemic cells.
A team of specialist doctors led by Neeraj Sidharth, head of bone and marrow
transplant programme at Amrita Institute, began this treatment after the girl's
condition slipped into a life-threatening stage even after two cycles of
chemotherapy.
The unique procedure is based on immunological killing of leukemic cells.
The result was a success, say AIMS experts.
"Worldwide cellular therapy has been done in a more sophisticated and costly manner in select centres at North America. What we attempted was similar to what has been already tried in Israel and China and published in reputed scientific journals," said Sidharth, who was guided by experts in the field from Johns Hopkins Hospital, Baltimore, US, and from China.
Unlike normal treatment for acute blood cancer, heavy dose of chemotherapy is not required for this procedure.
Microtransplant is cost effective and the patient needs to be hospitalised for just three weeks.
"The success of the treatment protocol is a major breakthrough and opens up a window of opportunity for those select patients with relapsed and refractory leukaemia," Sidharth added.
Source: Medindia
Advertisement
The unique procedure is based on immunological killing of leukemic cells.
The result was a success, say AIMS experts.
"Worldwide cellular therapy has been done in a more sophisticated and costly manner in select centres at North America. What we attempted was similar to what has been already tried in Israel and China and published in reputed scientific journals," said Sidharth, who was guided by experts in the field from Johns Hopkins Hospital, Baltimore, US, and from China.
Unlike normal treatment for acute blood cancer, heavy dose of chemotherapy is not required for this procedure.
Microtransplant is cost effective and the patient needs to be hospitalised for just three weeks.
"The success of the treatment protocol is a major breakthrough and opens up a window of opportunity for those select patients with relapsed and refractory leukaemia," Sidharth added.
Source: Medindia
Advertisement
Advertisement
|
Advertisement